SciSparc Ltd. (SPRC) stock
SPRCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.35−0.00 (-0.62%)
Close on Nov 13, 2026Market cap $129.04KP/E 0.0Yield –
SciSparc r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $2.10M, up 22.8% from the year before. The highest annual figure on record is $2.80M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.10M | +22.8% |
| FY2024 | Dec 31, 2024 | $1.71M | +4.0% |
| FY2023 | Dec 31, 2023 | $1.64M | -41.5% |
| FY2022 | Dec 31, 2022 | $2.80M | +40.9% |
| FY2021 | Dec 31, 2021 | $1.99M | +206.6% |
| FY2020 | Dec 31, 2020 | $649.00K | -60.4% |
| FY2019 | Dec 31, 2019 | $1.64M | -39.5% |
| FY2018 | Dec 31, 2018 | $2.71M | +39.5% |
| FY2017 | Dec 31, 2017 | $1.94M | +162.6% |
| FY2016 | Dec 31, 2016 | $740.00K | – |
| FY2015 | Dec 31, 2015 | -$240.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2018 | Jun 30, 2018 | $650.00K | – |
| Q2 FY2017 | Jun 30, 2017 | $455.00K | – |
See a number that looks wrong?